Get started
Author

Katya Sapunarova

Observed names: K Sapunarova, K. Sapunarova, Katya G. Sapunarova, Sapunarova, Katya
Observed institution: Medical University Plovdiv
ORCID: 0000-0001-9892-7979
Observed ORCID: 0000-0001-9892-7979
OpenAlex ID: A5008544296
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
2021 · Matthew J Matasar, Marcelo Capra, et al. · The Lancet Oncology · 142
Differentiation of Benign and Malignant Breast Lesions Using ADC Values and ADC Ratio in Breast MRI
2022 · Silvia Tsvetkova, Katya Doykova, et al. · Diagnostics · 20
PDF
Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia
2020 · Katya Sapunarova, Vesselina Goranova-Marinova, et al. · Annals of Medicine · 12
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
2026 · David J. Kuter, Katsuhiro Miura, et al. · New England Journal of Medicine · 10
Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities
2020 · Pencho G. Georgiev, Katya G. Sapunarova, et al. · Folia Medica · 2
PDF
Abstract A32: Copanlisib plus rituximab vs placebo plus rituximab in patients with follicular lymphoma: 1-year follow-up of the Phase III, randomized CHRONOS-3 trial
2022 · Marcelo Capra, Fangfang Lv, et al. · Blood Cancer Discovery · 1
P1138: Copanlisib + Rituximab Vs Rituximab + Placebo in Patients With Relapsed Indolent Non-hodgkin Lymphoma (nhl): Updated Safety and Efficacy From the Phase Iii Chronos-3 Trial
2022 · P. L. Zinzani, M. Özcan, et al. · HemaSphere · 1
Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab
2021 · Matthew J. Matasar, Marcelo Capra, et al. · Blood · 1
Application of low intensity laser radiation in extravasal infiltrates caused by cytostatics in children with acute leukemia.
1999 · V Goranova, M Marinckiev, et al. · PubMed · 1
Changing the treatment paradigm in beta thalassemia
2026 · Katya Sapunarova · Folia Medica
Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)
2021 · Matthew J. Matasar, Marcelo Capra, et al. · Cancer Research
Chronos‐3: Randomized Phase Iii Study of Copanlisib Plus Rituximab Vs Rituximab/placebo in Relapsed Indolent Non‐hodgkin Lymphoma (inhl)
2021 · P. L. Zinzani, M. Capra, et al. · Hematological Oncology
PDF
Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
2021 · Matthew J. Matasar, Marcelo Capra, et al. · Journal of Clinical Oncology
CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL)
2021 · Pier Luigi Zinzani, Marcelo Capra, et al. · Murdoch University Research Portal
Проучване върху костната минерална плътност и маркери на костния метаболизъм при български пациенти с трансфузионно- зависима бета- таласемия на възраст над 18 години
2020 · Сапунарова, Катя, Sapunarova, Katya · Bulgarian Portal for Open Science
Works count: 15
Citation count: 190
H-index: 4
I10-index: 4
Year
Topic
Type